Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases. The early infiltration by HIV-1 into the nervous system can cause pri...Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases. The early infiltration by HIV-1 into the nervous system can cause primary and/or secondary neurological complications. The most common neurocognitive disorder is AIDS Dementia Complex (ADC). In developing countries of Asia the three most opportunistic infections are tuberculosis (TB), cryptococcosis, and Pneumocystis carinii pneumonia. Therefore, it is expected that secondary neurological complications due to TB and cryptococcosis will be the most common cause of morbility and mortality in HIV-1/AIDS cases in China. Research of NeuroAIDS in China is necessary to understand the impact and the biology of HIV-1 in the nervous system. Future studies would include, the molecular epidemiology and the description of opportunistic infections associated to HIV-1; the neuropathological description of primary and secondary HIV-1 complications in different groups; the HIV-1 neurot- ropism and immune response studies for China’s unique HIV-1 strains and recombinant forms derived from the nervous system, including experimental models such as the use of transgenic rats; and the study of potential resistant virus, primarily when the anti-retroviral therapy (ART) has not full access in the brain.展开更多
Objective：To assess the long-term（up to 6 months）safety profile of a 3-month regimen of NeuroAiD for acute ischemic stroke.Methods：A total of 190 patients with acute ischemic stroke were identified for eligibility...Objective：To assess the long-term（up to 6 months）safety profile of a 3-month regimen of NeuroAiD for acute ischemic stroke.Methods：A total of 190 patients with acute ischemic stroke were identified for eligibility in a randomized,double-blind,placebo-controlled clinical trial,of which 150 patients allocated to either receiving NeuroAiD（80 cases）or placebo（70 cases）were analyzed after dropouts due to absence of baseline data,early death,or noncompliance.Both groups received treatment for three months and followed up for another three months after the completion of the treatment.Occurrence of clinical adverse events and laboratory parameters were assessed at 1 month,3 months（while under treatment）and 6 months（3 months after the completion of treatment）.Statistical comparisons between groups were performed using chi-square test or t-test whenever appropriate.Results：The two groups had comparable baseline characteristics.Mild nausea was more commonly reported in patients taking NeuroAid compared with placebo（P=0.01）,of which 9 out of10 were observed only during the first month of treatment.However,none of the adverse events reported were considered severe or required discontinuation of the study drug.There was no significant change observed in mean arterial blood pressure,haemoglobin,renal and liver laboratory parameters during treatment with NeuroAid and up to 3 months after completion of a 3-month regimen.Conclusion：NeuroAiD is safe and does not affect hematologic,hepatic,and renal functions during and long after completion of treatment.展开更多
文摘Neurological complications associated with HIV-1/AIDS are being recognized with a high frequency that parallels the increased number of AIDS cases. The early infiltration by HIV-1 into the nervous system can cause primary and/or secondary neurological complications. The most common neurocognitive disorder is AIDS Dementia Complex (ADC). In developing countries of Asia the three most opportunistic infections are tuberculosis (TB), cryptococcosis, and Pneumocystis carinii pneumonia. Therefore, it is expected that secondary neurological complications due to TB and cryptococcosis will be the most common cause of morbility and mortality in HIV-1/AIDS cases in China. Research of NeuroAIDS in China is necessary to understand the impact and the biology of HIV-1 in the nervous system. Future studies would include, the molecular epidemiology and the description of opportunistic infections associated to HIV-1; the neuropathological description of primary and secondary HIV-1 complications in different groups; the HIV-1 neurot- ropism and immune response studies for China’s unique HIV-1 strains and recombinant forms derived from the nervous system, including experimental models such as the use of transgenic rats; and the study of potential resistant virus, primarily when the anti-retroviral therapy (ART) has not full access in the brain.
基金Supported by funds from the Joundishapour Medical University
文摘Objective：To assess the long-term（up to 6 months）safety profile of a 3-month regimen of NeuroAiD for acute ischemic stroke.Methods：A total of 190 patients with acute ischemic stroke were identified for eligibility in a randomized,double-blind,placebo-controlled clinical trial,of which 150 patients allocated to either receiving NeuroAiD（80 cases）or placebo（70 cases）were analyzed after dropouts due to absence of baseline data,early death,or noncompliance.Both groups received treatment for three months and followed up for another three months after the completion of the treatment.Occurrence of clinical adverse events and laboratory parameters were assessed at 1 month,3 months（while under treatment）and 6 months（3 months after the completion of treatment）.Statistical comparisons between groups were performed using chi-square test or t-test whenever appropriate.Results：The two groups had comparable baseline characteristics.Mild nausea was more commonly reported in patients taking NeuroAid compared with placebo（P=0.01）,of which 9 out of10 were observed only during the first month of treatment.However,none of the adverse events reported were considered severe or required discontinuation of the study drug.There was no significant change observed in mean arterial blood pressure,haemoglobin,renal and liver laboratory parameters during treatment with NeuroAid and up to 3 months after completion of a 3-month regimen.Conclusion：NeuroAiD is safe and does not affect hematologic,hepatic,and renal functions during and long after completion of treatment.
